Skip to main content
OpenTrials

Clinical trial condition

Chromophobe Renal Cell Carcinoma

Explore clinical trials studying Chromophobe Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

13 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Chromophobe Renal Cell Carcinoma trial results

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382

Conditions
Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 582 locations
View Trial Details
Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825

Conditions
Adenocarcinoma, Adenoid Cystic Carcinoma, Albinism, +58 more
Locations
  • University of Michigan Hospitals Ann Arbor, Michigan, United States
  • Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Oregon Health & Science University Portland, Oregon, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)

NCT03685448

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +19 more
Locations
  • Border Medical Oncology Research Unit / The Border Cancer Hospital Albury, New South Wales, Australia
  • Campbelltown Hospital Campbelltown, New South Wales, Australia
  • St George Hospital Kogarah, New South Wales, Australia
  • Macquarie University Hospital Macquarie Park, New South Wales, Australia
View Trial Details
Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

NCT00126503

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +19 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber Harvard Cancer Center Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

NCT04413123

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +21 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Brigham & Woman's Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • UT Southwestern Medical Dallas, Texas, United States
View Trial Details

Related conditions